Navarro-Carpentieri D, Castillo-Hernandez MDC, Majluf-Cruz K, Espejo-Godinez G, Carmona-Olvera P, Moreno-Hernandez M, et al. Impact of Classical Risk Factors for Arterial or Venous Thrombosis in Patients With Antiphos-pholipid Syndrome. clin Appl Thromb Hemost. 2017 Jan 1:1076029617727859.

Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol. 2007 Apr; 44(2): 62-69.

Park MS, Perkins SE, Spears GM, Ashrani AA, Leibson CL, Boos CM, Harmsen WS,Jenkins DH, Bailey KR, Ballman KV, Heit JA. Risk factors for venous thromboembolism after acute trauma: A population-based case-cohort study. Thromb Res. 2016 Aug;144:40-5.

Giordano NJ, Jansson PS, Young MN,Hagan KA, Kabrhel C. Epidemiology,Pathophysiology, Stratification, and Natural History of Pulmonary Embolism. Tech Vasc Interv Radiol. 2017 Sep;20(3):135-140.

Kesieme E, Kesieme C, Jebbin N, Irekpita E, Dongo A. Deep vein thrombosis: a clinical review. Journal of Blood Medicine 2011:2 59–69.

Fuji T, Akagi M, Abe Y, Oda E, Matsubayashi D, Ota K, et al. Incidence of venous thromboembolism and bleeding events in patients with lower extremity orthopedic surgery: a retrospective analysis of a Japanese healthcare database. J Orthop Surg Res. 2017 Apr 4;12(1):55.

Wang C, Zhai Z, Yang Y, Wu Q, Cheng Z, Liang L, et al.; China Venous Thromboembolism (VTE) Study Group. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest. 2010 Feb;137(2):254-62.

Yilmazel Ucar E, Araz O, Kerget B, Yilmaz N, Akgun M, Saglam L. Comparison of long-term outcomes of 50 and 100 mg rt-PA in the management of acute pulmonary thromboembolism. Clin Respir J. 2017 Oct 17.